Accordingly, the knockdown of FOXM1 or its downstream targets was found very effective in restoring standard chemotherapy sensitivity in many human cancers, including colorectal cancer [20, 32], Lung carcinoma [34], breast cancer [36], ovarian cancer [19], prostate cancer [21], esophageal cancer [8]. This evidence concerns the gene FOXM1 and prostate cancer.